Qiagen NV (QGEN.DE)

QGEN.DE on Xetra

20.33EUR
11:35am EST
Change (% chg)

€-0.05 (-0.25%)
Prev Close
€20.39
Open
€20.58
Day's High
€20.59
Day's Low
€20.05
Volume
803,460
Avg. Vol
432,792
52-wk High
€21.07
52-wk Low
€14.38

QGEN.DE

Chart for QGEN.DE

About

QIAGEN N.V., (QIAGEN) is a holding company, which provides sample and assay technologies. The consumable products such as sample and assay kits and automated instrumentation systems provides customers to transform raw biological samples into valuable molecular information.The Company serves four customer classes: Molecular... (more)

Overall

Beta: 0.35
Market Cap(Mil.): €4,947.05
Shares Outstanding(Mil.): 239.71
Dividend: --
Yield (%): --

Financials

  QGEN.DE Industry Sector
P/E (TTM): 36.95 194.30 40.64
EPS (TTM): 0.55 -- --
ROI: 3.90 -1.13 18.12
ROE: 5.62 -2.98 18.97
Search Stocks

Qiagen profit declines as U.S. sales of HPV tests slide

- German genetic test maker Qiagen NV said its quarterly profit slid 24 percent as U.S. sales of its human papillomavirus (HPV) test declined and the dollar strengthened.

28 Jan 2015

CORRECTED-Qiagen profit declines as U.S. sales of HPV tests slide

Jan 28 - German genetic test maker Qiagen NV said its quarterly profit slid 24 percent as U.S. sales of its human papillomavirus (HPV) test declined and the dollar strengthened.

28 Jan 2015

BRIEF-Qiagen N.V. expects 2015 adj net sales to rise about 4% at constant exchange rates

* Qiagen N.V. Q4 adjusted earnings per share $0.25; q4 earnings per share $0.11

28 Jan 2015

Roche says licenses EGFR pathway-related intellectual property to QIAGEN

ZURICH, Jan 14 - Swiss drugmaker Roche said on Wednesday it had entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents, pertaining to the detection of mutations in the EGFR pathway.

14 Jan 2015

BRIEF-Qiagen Marseille receives offer from management team to acquire some of its assets

* Receives offer from its management team to acquire some of its assets

22 Dec 2014

Qiagen Q3 profit rises on demand for disease diagnostics

Oct 29 - German genetic testing specialist Qiagen NV reported a 6 percent increase in adjusted third-quarter earnings, slightly ahead of analysts' average forecast, helped by demand for its automated diagnostics gear and for test kits co-developed with drugmakers.

29 Oct 2014

BRIEF-Qiagen announces broad agreement with Astellas Pharma

* Qiagen announces broad agreement with astellas pharma to develop companion diagnostics

28 Oct 2014

BRIEF-Qiagen Marseille H1 net income falls to 2.8 mln euros from 5.6 mln euros last year

* H1 net income 2.8 million euros versus 5.6 million euros in H1 2013

11 Sep 2014

Earnings vs. Estimates

Search Stocks